APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Geographic Atrophy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Geographic Atrophy Drugs Market Outlook and Growth Opportunities 2026

Report ID 173994980429 December 2025194 pages

Choose your research edition.

Industry ResearchGeographic Atrophy Drugs Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Geographic Atrophy Drugs Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Geographic Atrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Geographic Atrophy Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Geographic Atrophy Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Geographic Atrophy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Geographic Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Geographic Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Geographic Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Geographic Atrophy Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Geographic Atrophy Drugs market include Apellis Pharmaceuticals and Astellas Pharma among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Geographic Atrophy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Geographic Atrophy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Geographic Atrophy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Geographic Atrophy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Geographic Atrophy Drugs Segment by Company

Apellis Pharmaceuticals

Astellas Pharma

Geographic Atrophy Drugs Segment by Type

Avacincaptad

Pegcetacoplan

Other

Geographic Atrophy Drugs Segment by Application

Hospital

Clinic

Other

Geographic Atrophy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Geographic Atrophy Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Geographic Atrophy Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Geographic Atrophy Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Geographic Atrophy Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Geographic Atrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Geographic Atrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Geographic Atrophy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Geographic Atrophy Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Geographic Atrophy Drugs industry.

Chapter 3: Detailed analysis of Geographic Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Geographic Atrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Geographic Atrophy Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Geographic Atrophy Drugs Industry Trends Table 2. Geographic Atrophy Drugs Industry Drivers Table 3. Geographic Atrophy Drugs Industry Opportunities and Challenges Table 4. Geographic Atrophy Drugs Industry Restraints Table 5. Global Geographic Atrophy Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Geographic Atrophy Drugs Revenue Share by Company (2021-2026) Table 7. Global Geographic Atrophy Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Geographic Atrophy Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Geographic Atrophy Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Geographic Atrophy Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Geographic Atrophy Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Geographic Atrophy Drugs Company, Product Type & Application Table 13. Global Geographic Atrophy Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Geographic Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Avacincaptad Table 18. Significant Companies of Pegcetacoplan Table 19. Significant Companies of Other Table 20. Global Geographic Atrophy Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Geographic Atrophy Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Geographic Atrophy Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Geographic Atrophy Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Geographic Atrophy Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Geographic Atrophy Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Geographic Atrophy Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Geographic Atrophy Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Geographic Atrophy Drugs Sales Value Share by Type (2021-2026) Table 29. Global Geographic Atrophy Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Other Table 33. Global Geographic Atrophy Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Geographic Atrophy Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Geographic Atrophy Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Geographic Atrophy Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Geographic Atrophy Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Geographic Atrophy Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Geographic Atrophy Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Geographic Atrophy Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Geographic Atrophy Drugs Sales Value Share by Application (2021-2026) Table 42. Global Geographic Atrophy Drugs Sales Value Share by Application (2027-2032) Table 43. Global Geographic Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Geographic Atrophy Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Geographic Atrophy Drugs Sales Market Share by Region (2021-2026) Table 46. Global Geographic Atrophy Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Geographic Atrophy Drugs Sales Market Share by Region (2027-2032) Table 48. Global Geographic Atrophy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Geographic Atrophy Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Geographic Atrophy Drugs Sales Value Share by Region (2021-2026) Table 51. Global Geographic Atrophy Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Geographic Atrophy Drugs Sales Value Share by Region (2027-2032) Table 53. Global Geographic Atrophy Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Geographic Atrophy Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Geographic Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Geographic Atrophy Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Geographic Atrophy Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global Geographic Atrophy Drugs Sales Market Share by Country (2021-2026) Table 59. Global Geographic Atrophy Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Geographic Atrophy Drugs Sales Market Share by Country (2027-2032) Table 61. Global Geographic Atrophy Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Geographic Atrophy Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Geographic Atrophy Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Geographic Atrophy Drugs Sales Value Market Share by Country (2027-2032) Table 65. Apellis Pharmaceuticals Company Information Table 66. Apellis Pharmaceuticals Business Overview Table 67. Apellis Pharmaceuticals Geographic Atrophy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Apellis Pharmaceuticals Geographic Atrophy Drugs Product Portfolio Table 69. Apellis Pharmaceuticals Recent Development Table 70. Astellas Pharma Company Information Table 71. Astellas Pharma Business Overview Table 72. Astellas Pharma Geographic Atrophy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Astellas Pharma Geographic Atrophy Drugs Product Portfolio Table 74. Astellas Pharma Recent Development Table 75. Key Raw Materials Table 76. Raw Materials Key Suppliers Table 77. Geographic Atrophy Drugs Distributors List Table 78. Geographic Atrophy Drugs Customers List Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Geographic Atrophy Drugs Product Image Figure 2. Global Geographic Atrophy Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Geographic Atrophy Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Geographic Atrophy Drugs Sales (2021-2032) & (K Units) Figure 5. Global Geographic Atrophy Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Geographic Atrophy Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Avacincaptad Image Figure 10. Pegcetacoplan Image Figure 11. Other Image Figure 12. Global Geographic Atrophy Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Geographic Atrophy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Geographic Atrophy Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Geographic Atrophy Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Geographic Atrophy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Geographic Atrophy Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global Geographic Atrophy Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Geographic Atrophy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Geographic Atrophy Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Geographic Atrophy Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Geographic Atrophy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Geographic Atrophy Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Geographic Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Geographic Atrophy Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Geographic Atrophy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Geographic Atrophy Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Geographic Atrophy Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Geographic Atrophy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Geographic Atrophy Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Geographic Atrophy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Geographic Atrophy Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Geographic Atrophy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Geographic Atrophy Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Geographic Atrophy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Geographic Atrophy Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Geographic Atrophy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Geographic Atrophy Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Geographic Atrophy Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Avacincaptad
  • Pegcetacoplan
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Apellis Pharmaceuticals
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Geographic Atrophy Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Geographic Atrophy Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Geographic Atrophy Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Geographic Atrophy Drugs Market Dynamics
  1. 2.1 Geographic Atrophy Drugs Industry Trends
  2. 2.2 Geographic Atrophy Drugs Industry Drivers
  3. 2.3 Geographic Atrophy Drugs Industry Opportunities and Challenges
  4. 2.4 Geographic Atrophy Drugs Industry Restraints
3 Geographic Atrophy Drugs Market by Company
  1. 3.1 Global Geographic Atrophy Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Geographic Atrophy Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Geographic Atrophy Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Geographic Atrophy Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Geographic Atrophy Drugs Company Ranking (2024-2026)
  6. 3.6 Global Geographic Atrophy Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Geographic Atrophy Drugs Company Product Type and Application
  8. 3.8 Global Geographic Atrophy Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Geographic Atrophy Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Geographic Atrophy Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Geographic Atrophy Drugs Market by Type
  1. 4.1 Geographic Atrophy Drugs Type Introduction
  2. 4.1.1 Avacincaptad
  3. 4.1.2 Pegcetacoplan
  4. 4.1.3 Other
  5. 4.2 Global Geographic Atrophy Drugs Sales Volume by Type
  6. 4.2.1 Global Geographic Atrophy Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Geographic Atrophy Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Geographic Atrophy Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Geographic Atrophy Drugs Sales Value by Type
  10. 4.3.1 Global Geographic Atrophy Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Geographic Atrophy Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Geographic Atrophy Drugs Sales Value Share by Type (2021-2032)
5 Geographic Atrophy Drugs Market by Application
  1. 5.1 Geographic Atrophy Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Geographic Atrophy Drugs Sales Volume by Application
  6. 5.2.1 Global Geographic Atrophy Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Geographic Atrophy Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Geographic Atrophy Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Geographic Atrophy Drugs Sales Value by Application
  10. 5.3.1 Global Geographic Atrophy Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Geographic Atrophy Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Geographic Atrophy Drugs Sales Value Share by Application (2021-2032)
6 Geographic Atrophy Drugs Regional Sales and Value Analysis
  1. 6.1 Global Geographic Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Geographic Atrophy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Geographic Atrophy Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Geographic Atrophy Drugs Sales by Region (2027-2032)
  5. 6.3 Global Geographic Atrophy Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Geographic Atrophy Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Geographic Atrophy Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Geographic Atrophy Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Geographic Atrophy Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Geographic Atrophy Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Geographic Atrophy Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Geographic Atrophy Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Geographic Atrophy Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Geographic Atrophy Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Geographic Atrophy Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Geographic Atrophy Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Geographic Atrophy Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Geographic Atrophy Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Geographic Atrophy Drugs Sales Value Share by Country, 2025 VS 2032
7 Geographic Atrophy Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Geographic Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Geographic Atrophy Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Geographic Atrophy Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Geographic Atrophy Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Geographic Atrophy Drugs Sales by Country (2027-2032)
  6. 7.4 Global Geographic Atrophy Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Geographic Atrophy Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Geographic Atrophy Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Geographic Atrophy Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Geographic Atrophy Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Geographic Atrophy Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Apellis Pharmaceuticals
  2. 8.1.1 Apellis Pharmaceuticals Company Information
  3. 8.1.2 Apellis Pharmaceuticals Business Overview
  4. 8.1.3 Apellis Pharmaceuticals Geographic Atrophy Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Apellis Pharmaceuticals Geographic Atrophy Drugs Product Portfolio
  6. 8.1.5 Apellis Pharmaceuticals Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Geographic Atrophy Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Geographic Atrophy Drugs Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Geographic Atrophy Drugs Value Chain Analysis
  2. 9.1.1 Geographic Atrophy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Geographic Atrophy Drugs Sales Mode & Process
  6. 9.2 Geographic Atrophy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Geographic Atrophy Drugs Distributors
  9. 9.2.3 Geographic Atrophy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst